An ambitious 10‐year collaborative program is described to invent, design, demonstrate, and support commercialization of integrated biopharmaceutical manufacturing technology intended to transform the industry.
It’s a joint publication from industry, FDA and NIIMBL
Public-private partnership could help coronavirus vaccine developers increase thermal stability, strengthen potency assays and fine-tune adventitious agent testing, among other things.
The last decade in biopharmaceutical manufacturing has brought a considerable amount of change to how drugs are developed and manufactured. Advances in science and technology have resulted in more diversified pipelines with increasingly complex molecules. Seeking faster ways to bring novel drugs to market while meeting stringent product quality...
As of the end of April, the World Health Organization was tracking 71 coronavirus vaccines in preclinical trials, with five additional candidates already in clinical trials. Given how recently the COVID-19 pandemic began spreading, it might seem promising that there’s already a lot of activity on the immunization front.
With so many potential...
Epidemiologists or "disease detectives" will say it takes at least 10 years, on average, to develop, test and produce a new anti-viral vaccine.
Given this tedious timescale, news that biotech and pharmaceutical firms worldwide are aiming to have a new vaccine against COVID-19 available in as little as only 18 months is historic and unheard of.
The...
